EDUCATIONAL COMMENTARY D-DIMER UPDATE

Similar documents
D-dimer Assay Issues and Standardization: QMP-LS Studies

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2

SEED Coagulation. Sysmex Educational Enhancement and Development April 2014

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

Basic coagulation applications and case studies

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

Physician Orders - Adult

Use of Chromogenic Assay of Factor X to Accept or Reject INR Results in Warfarin Treated Patients

Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase

ROTEM Basic Interpretation Guide

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?

Hematology Emergencies: Problems with Platelets

Alere Triage MeterPro D-Dimer METHOD AND SAMPLE COLLECTION

Coagulation in perspective: Blood management. Objectives

Profibrinolytic diabody targeting PAI-1 and TAFI for treatment of acute thrombotic disorders

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.

LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

Guideline on core SmPC for human fibrinogen products

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005

Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

If not heparin for bypass then what? Dr Tony Moriarty Consultant Cardiac Anaesthetist Birmingham United Kingdom

Generate Knowledge. STic Expert HIT: for a rapid and confident exclusion of Heparin Induced Thrombocytopenia. Jamal Barsheed

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1

Antithrombin Deficiency

Practical Applications of Immunology (Chapter 18) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Eastern Campus

Sign up to receive ATOTW weekly -

Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin

Human Plasmin Activity Assay ELISA Kit

Blood is 55% Plasma (Liquid)

Scottish Medicines Consortium

Biological evaluation of medical devices. Part 4: Selection of tests for interactions with blood

Anti- THrombosis with Enoxaparin in intubated Adolescents

2 Thomas G. DeLoughery

Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey

Fibrin Clots Are Equilibrium Polymers That Can Be Remodeled Without Proteolytic Digestion

Marcia L. Zucker, Ph.D. ZIVD LLC

Physiology Unit 3 HEMATOLOGY

On-Site Specialty Analyzer

DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

4/25/2009. Other 8% Thrombosis? Stenosis 8% 74% Infection 10%

Abbreviations: DVT deep vein thrombosis; LMWH low-molecular-weight heparin; PE pulmonary embolism; VTE venous thromboembolism

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Common Inherited Bleeding Disorders

FORENSIC SEROLOGY. Chapter PRENTICE HALL 2008 Pearson Education, Inc. Upper Saddle River, NJ 07458

AssayMax Human Antithrombin III ELISA Kit

Perioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle

Initial Dose 10,000 units Every 4 to 6 hours 5,000 to 10,000 units. Intermittent IV injection

Peer Review Report # 2. Low Molecular Weight Heparins

Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

The Clinical Use and Immunologic Impact of Thrombin in Surgery

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK

Pharmacotherapy Resuscitation in Acute Traumatic Coagulopathy: Ready for Prime Time? September 29, 2017

Note: The taller 100 x 13 mm tube is not designed to run on the ACL TOP. Plasma after centrifugation of these tubes must be placed in sample cups.

Diagnostic Microbiology

HEMOSTASIS IN SURGERY

A Rapid, Quantitative Determination of Clottable Fibrinogen Unaffected by Heparin

International Society Laboratory Hematology Milan, May Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016

Antibodies and Antigens In the blood bank

Challenges of VTE Prophylaxis in. Orthopaedics. Prevalence of DVT in Orthopaedic Surgery Without Prophylaxis

FACTOR XIII DEFICIENCY IN PAKISTAN

Enoxaparin sodium 150mg (equivalent to 15,000 IU anti-xa. activity) in 0.2ml water for injections. activity) in 0.4ml water for injections

Overview of Anatomy and Physioloy II Second Year Students

*NCCT is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program, provider #122.

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD

Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved.

Analysis of Clinical Trials with Multiple Objectives

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

NEW ORAL ANTICOAGULANTS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN THE FOOT AND ANKLE

The Story of the Platelet Clump. Wayne Hall MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA

2015 Catalogue Coagulation

Immunological Techniques in Research and Clinical Medicine. Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016

See external label 2 C-8 C Σ=96 tests Cat # 5201Z CARCINOEMBRYONIC ANTIGEN (CEA) ENZYME IMMUNOASSAYTEST KIT CEA ELISA. Cat # 5201Z

Pre-Analytic Issues in Laboratory Medicine

Current Trends at FDA: Implications for Data Requirements

Table of Contents. Introduction. Worldwide Market and Technology Overview

ENOXAPARIN AHFS??? Class: Low molecular weight heparin (LMWH).

Fibrinogen ELISA. For the quantitative determination of fibrinogen in biological fluids, serum, and plasma.

Product Data Sheet - TRUEMAB

Canine Fibrinogen ELISA

Antibodies and Antigens in the Blood Bank 9/7/2015 NAHLA BAKHAMIS 1

Cyfra 21-1 IRMA. Product information Information about other products is available at: Userś Manual DE52100

Improving the Limit of Detection of Lateral Flow Assays using 3DNA Technology

How to Maximize Resources, Optimize Quality and Minimize Costs in the Coagulation Laboratory- by the Laboratory Whisperer

Handouts. Handouts 1/28/2016. Understanding the Misunderstood Disease of Heparin Induced Thrombocytopenia (HIT) OKSANA VOLOD M.D.

OERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY

Biomarkers for Delirium

The Coagulation Workup In The Office Setting

Transcription:

EDUCATIONAL COMMENTARY D-DIMER UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing Education menu on the left side of the screen. Learning Outcomes Upon completion of this exercise, the participant should be able to: describe the limitations of the D-dimer test when the result is positive. define clinical decision rules and describe how they are used when evaluating venous thrombotic events. After the D-dimer antigen was first identified in the 1970s, it was proposed for a number of roles in clinical practice. Many of the proposed roles were evaluated and rejected, and new roles for patient monitoring and patient management have emerged for the D-dimer antigen. In a perfect world, finding the D-dimer antigen in plasma would mean that the patient has a significant clot (or thrombus) and that the clot is being dissolved by plasmin, resulting in a positive D-dimer test result. But the list of pathologic states resulting in positive findings is long. In addition, the D-dimer test result is reported to be elevated in many normal conditions. The D-dimer test result is most useful when found to be negative and is considered in light of the clinical presentation and the likelihood of abnormal clotting. If the application is narrowed to a negative finding and that negative result is used in context with clinical rules, the D-dimer test has a significant role in today s health care delivery system. D-Dimer and the Fibrin Strand Fibrin strands are generated when thrombin converts fibrinogen molecules to fibrin monomers. This involves removal of fibrinopeptides from fibrinogen. The fibrin monomers polymerize to form insoluble fibers that interlace the platelet plug. These polymers are then cross-linked by factor XIII. The chemical bonds that first hold the polymer together are weak, but the bonds formed by factor XIIIa are strong covalent bonds.

Figure 1 illustrates the final phase of fibrin formation and the cross-links. When plasmin dissolves a clot, the fibrin strand is cut between the D and E regions on the fibrin. Plasmin does not cut the covalent bonds made by factor XIIIa, so the end result is fragments of polymer (called oligomers ), which contain cross-linked D antigens. These oligomers are detected by the D-dimer antibody. The oligomers vary in size, which presents some problems in the quantitation of D-dimer because the antigen is present on a diverse spectrum of fragments. It does not detect a single molecule, but detects the D-dimer identity on large and small pieces of fibrin.

Figure 2 illustrates the digestion of fibrin by plasmin and the resulting fragments containing D-dimer identity. Measurement Techniques The measurement techniques developed earlier used latex beads coated with anti-d-dimer antibody. When the antigen was present in sufficient quantity, the beads agglutinated forming a visible reaction. It was not quantitative but could be used as a semiquantitative test by testing various dilutions. The next generation of tests looked at the rate of bead agglutination and correlated that rate with the quantity of antigen present. Studies showed that test sensitivity depended on the size of fragments. Present-day measurement techniques provide sensitive quantitative analysis. These include enzyme-linked immunoabsorbent assays (ELISA), fluorescence endpoint assays, immunofiltration assays, turbidimetric assays,

and whole blood rapid assays. Rapid assays, such as the immunofiltration and whole blood methods, offer the advantage of a shortened turnaround time, thus facilitating clinical decision making. No one perfect assay is available. Each test system requires tradeoffs of speed, practicality, sensitivity, and specificity. The wide variety of measurement platforms requires each laboratory to determine a cutoff value above which the D-dimer is considered positive for clinical decisions. This cutoff value must be clearly communicated to the clinician. The quantitative D-dimer level provides evidence about the presence or absence of a thrombus in the patient s circulation. If the D-dimer result is below the cutoff value, the patient is unlikely to have a thrombus. Conversely, a high level means a higher likelihood of a thrombus. The tricky part is that for most patients, a thrombus is a normal response to injury. But for other patients the thrombus is pathologic, often life threatening, and is commonly called thrombosis or a thromboembolism. What Is Venous Thromboembolism? A clot that blocks a vein is a venous thromboembolism (VTE). The term is most commonly used to describe a deep vein thrombosis (DVT) or a pulmonary embolism (PE). The DVT is a clot in a vein that is deep in the body, and DVTs are most commonly found in major leg veins (such as the femoral or popliteal) and in major pelvic veins. Clots may also occur in major arm veins, but these are rare. PE is blockage of the main artery to the lung and is most commonly due to the thrombus from a deep vein traveling through the circulation to the lung. The gold standard for diagnosis of DVT is venography, a technique that takes radiographs of veins after a special dye is injected near the site via a catheter inserted in the groin. This is an expensive and invasive procedure. Other techniques use ultrasound, but these are also expensive and inefficient when compared to a blood test. The D-dimer test has been proposed as an efficient and inexpensive way to rule out VTE and has been found to be effective when used with appropriate clinical prediction rules. What Are Clinical Prediction Rules? Clinical prediction rules are scoring criteria on the likelihood of VTE used to reach the correct diagnosis while minimizing the need for expensive sonograms. Several validated clinical prediction rules are used for VTE but all work by evaluating patient history and clinical presentation. One common rule set, called the Wells method, includes: Questions on history of cancer treatment Recent surgery that required general anesthesia Lower extremity weakness, paralysis, or immobilization Tenderness and swelling of the leg and calf Previously documented DVT Likelihood of other diagnoses In every method, each answer is scored numerically. The scores are totaled, and the likelihood of VTE is determined as either likely or unlikely.

The specific rules for DVT and PE are different but follow a similar strategy. If the DVT is likely and the patient has a high pre-test probability, the rule points to venography to make the diagnosis. If DVT probability is determined to be low to moderate, the D-dimer test is performed. If the D-dimer test result is low (negative), the diagnosis of VTE is excluded, but if the D-dimer is elevated (positive), the rule is to proceed with the venography for diagnosis. Used this way, D-dimer test is reported to have a high negative-predictive value for VTE, i.e., a high number of patients with negative test results are correctly diagnosed. Use of the predictive rules and the D-dimer test speeds the diagnosis and saves healthcare dollars. Figure 3 shows a simplified version of the algorithm for DVT. Monitoring and Tailoring Anticoagulant Treatment Following VTE Periodically measuring the D-dimer level on outpatients undergoing anticoagulant therapy following VTE helps to tailor the therapy and predict recurrence according to two recent studies. Patients are usually anticoagulated with oral anticoagulants for some period after hospitalization for VTE, but the optimum length of this period is unknown. In the first study, the patients were treated for three months, and then the D-dimer level was tested one month later by a simple qualitative method. Patients who were positive for D-dimer had a significantly higher risk of recurrence, and this finding suggests that D-dimer testing could determine how long a patient should be treated. In the second study, patients were tested every two months for a year after cessation of anticoagulant therapy, and similar results were found. Studies like these suggest a possible solid application for the original simple latex agglutination test.

Testing for Disseminated Intravascular Coagulation The D-dimer is frequently listed as a fibrin-related marker to score patients for the likelihood of disseminated intravascular coagulation (DIC). But as in other clinical applications, the usefulness of the D-dimer result is limited by the sensitivity and lack of specificity of positive findings. Suggested Reading Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113:2878-2887. Cosmi B, Legnani C, Tosetto A, et al. Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood. 2010;115:481-488. Glossary Cross-link: a chemical bond between different chains of atoms in a polymer or other complex molecule Dimer: a molecule or molecular complex consisting of two identical molecules linked together Epitope: the part of an antigen molecule to which an antibody attaches itself; also called the antigenic determinant Oligomer: a polymer whose molecules consist of relatively few repeating units Plasmin: an enzyme derived from plasminogen that destroys blood clots Polymer: a substance with a molecular structure consisting chiefly or entirely of a large number of similar units bonded together ASCP 2011